CAD and hepatocellular carcinoma: Notably, comparing the discriminating power (AUC: 0.621) of the four-gene signature (BRCA1-CAD-CDC20-RBM8A) in Wang study [70], with an AUC of 0.656 in TCGA-HCC dataset and 0.740 in ICGC-HCC dataset, the superior performance of the two-gene combination (LCAT-CDC20) in this study was obvious.